SCHEMBL5800196

SCHEMBL5800196

COc1ccccc1-c1nc2ccccc2c(=O)n1CCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASR P41180 11/20 0.69
TP53 P04637 2/20 0.65
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
SMN1; SMN2 Q16637 3/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 2/20 0.58
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
PLA2G1B P04054 1/20 0.57
GAA P10253 1/20 0.57
ATG4B Q9Y4P1 1/20 0.57
ATM Q13315 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
GFER P55789 1/20 0.54
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5921199 0.85 CASR (0.75) CASRMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL12884883 0.82 CASR (0.53) CASRTP53MEN1KMT2ASMN1; SMN2
SCHEMBL4144024 0.82 TP53 (0.55) CASRTP53KMT2AALDH1A1USP2
SCHEMBL13851597 0.82 CASR (0.58) CASRTP53MEN1KMT2AALDH1A1
SCHEMBL5750037 0.81 CASR (0.73) CASRMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL5750178 0.81 CASR (1.00) CASRMEN1KMT2AGFER
SCHEMBL5799528 0.81 CASR (0.73) CASRMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3381858 0.81 CASR (0.72) CASRTP53ALDH1A1USP2TSHR
SCHEMBL1464727 0.81 ALDH1A1 (0.69) MEN1KMT2ASMN1; SMN2ALDH1A1USP2
SCHEMBL5780401 0.81 CASR (0.69) CASRTP53SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558260-A4 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMA INC (US) 2006-10-25 EP disclosed
US-20060052345-A1 Quinazolinone compounds as calcilytics NPS PHARMACEUTICALS, INC. (US) 2006-03-09 US disclosed
EP-1558260-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2005-08-03 EP disclosed
WO-2004041755-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052345-A1 Quinazolinone compounds as calcilytics CALCR, CALCRL, CASR CASR 3/4885TP53 3696/4885MEN1 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.